| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President and CEO | President &CEO | Head of Research &Development +4 more
2 companies
Sandrock Alfred is a President and CEO at VYGR, with reported holdings spanning 2 companies. Recent filings cover 0 purchases and 34 sales. Those positions are worth an estimated $6.3M at current prices.
Our model assigns Sandrock Alfred a middling insider score of 69/100, based on 9 past trades. Over a 12-month horizon, 71.4% of those trades were profitable, with an average 12-month return of +21.7%.
Sandrock Alfred's largest disclosed position is in BIIB as Head of Research &Development, worth about $4.5M. The recent filings there lean toward selling, a net 23,549 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Feb 9, 2016 | BIIB Biogen Inc. | EVP CMO Neuro &Neurodegenerat | Sale+OE | 852 | $246.54 | $210,052.08 | -9.9% | |
| Dec 4, 2015 | BIIB Biogen Inc. | EVP CMO Neuro &Neurodegenerat | Sell | 441 | $277.00 | $122,157.00 | -5.4% | |
| Mar 27, 2015 | BIIB Biogen Inc. | Grp SVP, Chief Medical Officer | Sell | 430 | $430.12 | $184,951.60 | -4.8% | |
| Mar 2, 2015 | BIIB Biogen Inc. | Grp SVP, Chief Medical Officer | Sell | 3,174 | $409.49 | $1,299,714.73 | -26.1% | |
| Feb 17, 2015 | BIIB Biogen Inc. | Grp SVP, Chief Medical Officer | Sell | 418 | $389.11 | $162,647.98 | -2.7% | |
| Feb 10, 2015 | BIIB Biogen Inc. | Grp SVP, Chief Medical Officer | Sell | 1,143 | $398.11 | $455,038.99 | -7.3% | |
| Feb 9, 2015 | BIIB Biogen Inc. | Grp SVP, Chief Medical Officer | Sale+OE | 856 | $398.05 | $340,730.80 | -5.5% |